GlycoEra AG is a biotech in Wädenswil, Switzerland, developing glycoengineered biologics using a proprietary platform technology for next‑generation therapeutics across multiple indications. Following our Series B financing, we are advancing GE8820—our precision IgG4‑targeted degrader—into first‑in‑human trials while expanding our pipeline of novel precision immunology therapies.